re: "Human trial showed that 2-73 and Donepzil give no benefit whilst the mice data said the reverse. "
Current evolutionary science has both humans and mice descending from the same shrew-like creature. In fact, all mammals. How the platypus figures into that I don't recall, further down the evolutionary tree maybe a duck fell in love with a mongoose. Maybe it proves that love conquers all, even interspecies reproductive incompatibilty. Could make for a cute Disney movie. :)
A shrew looks a lot like a mouse to me. There is the classic battle cry: "Are you mice or men?" Well, both, if you go far enough back in ancestry. Mice are popular for research because at a very basic "no frills" biological level, they are very similar to humans. Mainly they're used to establish initial safety. If the mice all die suddenly, that would be unfortuneate, but, well, better them than us, right?
Anyway, weren't the mice specially bred to develop AD? So, what the mouse results prove is that the Aricept (donepezil) component exhibitted synergy with 2-73 against AD that is strictly hereditary in origin. Considering that AD could be triggered by other factors such as infection, the aftermath of infection such as exosomes, or prolonged exposure to currently "acceptable" levels of heavy metals, Aricept's removal of the limiting factor on acetycholine level evidently becomes counter-productive at some point. The mice were in a sterile laboratory environment. That could account for a difference. 2-73 counteracts the effect of some kind of contamination. After 2-73 restores normal cell function, resumption of normal production would likely mean too much acetycholine due to the Aricept. I think I read that Aricept also binds to some receptors along the way. Maybe not the ones we want long term.
A quick 2-73 Plus patent would have been nice but I think they still have a shot at it due to Aricept having some utility at the start of treatment and 2-73 acting synergisically to counter Aricept's side-effects. This would defuse the patent examiner's complaint that they were simply additive. Otherwise, Anavex will qualify for a patent extension for however many years they were delayed in bringing their product to market due to FDA testing requirements.
